Roche Mulls Sub-Licensing Bird Flu Drug

Law360, New York (October 19, 2005, 12:00 AM EDT) -- Roche Pharmaceuticals is considering sub-licensing its avian flu treatment Tamiflu amid calls for patent overrides from politicians such as New York Senator Charles E. Schumer.

“We are prepared to discuss all available options, including granting sub-licenses, with any government or private company who approach us to manufacture Tamiflu or collaborate with us in its manufacturing,” William M. Burns, Roche Pharma Division CEO, said.

Roche recently donated 30 million Tamiflu capsules to the World Health Organization to “strike the initial outbreak,” according to WHO documents.

Roche also...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.